Compare Becton Dickinson and Co (BDX) vs Innodata Inc (INOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Innodata Inc — how do they compare? Becton Dickinson and Co trades at $149.95 (market cap $41.51B), while Innodata Inc trades at $67.46 (market cap $2.19B). The key difference: Becton Dickinson and Co is far larger — about 19× Innodata Inc's market cap, and Becton Dickinson and Co pays a 2.79% dividend while Innodata Inc pays none. Which is the better fit depends on your goals.
| BDX | INOD | |
|---|---|---|
Market Cap | $41.51B | $2.19B |
Sector | Health | Technology |
52-Week High | $185.39 | $121.50 |
52-Week Low | $135.49 | $34.45 |
Enterprise Value | $57.97B | $2.08B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
INOD trades at $68.12, up 0.47% today but down 33% over the past month. The stock shows strong fundamentals with revenue growth to $252M in 2025 and net income of $32M, while beating EPS estimates in recent quarters. Technical indicators signal a bearish trend, with resistance at $69 and support at $67. Recent news highlights AI-driven growth and a new CFO appointment.
Outlook remains positive due to AI demand and raised guidance, but high valuation (P/E 59.89) and customer concentration pose risks. Analyst consensus is bullish with a $130 price target, suggesting significant upside potential if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →
